QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor
Author | Danjuma, Mohammed I. |
Author | Sinha, Urshita |
Author | Fatima, Haajra |
Author | Mohamed, Mouhand F.H. |
Author | Nathoe, Hendrik |
Available date | 2024-02-14T11:20:46Z |
Publication Date | 2020-09-12 |
Publication Name | European Journal of Clinical Investigation |
Identifier | http://dx.doi.org/10.1111/eci.13407 |
Citation | Danjuma, M. I., Sinha, U., Fatima, H., Mohamed, M. F., & Nathoe, H. (2021). QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor. |
ISSN | 0014-2972 |
Abstract | We read with interest Monzani et al's report1 on QT pro-longation in COVID-19 patients on treatment with chloro-quine/hydroxychloroquine (CQ/HCQ). Her report highlights the therapeutic morbidities that have unfortunately evolved as part of the measures to control COVID-19 pandemic. Cardiac toxicity including QTc prolongation has been well established as part of the syndrome of adverse events associated with CQ/HCQ administration.2 Since the advent of the COVID-19 pandemic, there has been increasing reports of various phe-notypes of QTc prolongation and its sequelae in COVID-19 patients on treatment with CQ/HCQ. |
Language | en |
Publisher | Wiley-Blackwell |
Subject | QTc interval COVID-19 |
Type | Other |
Issue Number | 11 |
Volume Number | 50 |
ESSN | 1365-2362 |
Files in this item
This item appears in the following Collection(s)
-
COVID-19 Research [809 items ]
-
Medicine Research [1413 items ]